A mid-stage trial of Juno Therapeutics’ cancer killing T ... The US Food and Drug Administration said the ROCKET phase 2 trial can restart under a revised protocol using JCAR015 T-cells ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback